Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Exp Neurol. 2021 Aug 25;346:113838. doi: 10.1016/j.expneurol.2021.113838

Fig. 3: Contributions of CaV3.2 to stimulated CGRP release in healthy skin and sciatic nerve.

Fig. 3:

A. KCl-evoked CGRP release from hairy skin of C57BL/6J and CaV3.2 KO mice and inhibitory effect of combined HVA calcium channel blockers nifedipine (10 μM) and ω–conotoxin (1μM). B. AUC display of data in A and no effect of the CaV3.2 blocker TTAP2 (10μM). C. KCl-evoked CGRP release from sciatic nerve of C57BL/6J and CaV3.2 KO mice. D. AUC display of the data in A and effect of the CaV3.2 blocker TTA-P2 (10μM). Significant increases in CGRP release over baseline and significant differences between experimental groups are marked with a hashtag or an asterisk based on Wilcoxon matched pairs test and ANOVA repeated measurements, respectively.